Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Blastic plasmacytoid dendritic-cell neoplasm (BPDCN) is an aggressive hematologic malignancy.
• It arises from transformed plasmacytoid dendritic cells overexpressing IL3RA (CD123).
• Tagraxofusp is a novel CD123-directed cytotoxin targeting BPDCN cells.

Purpose of the Study:

• To evaluate the efficacy and safety of tagraxofusp in patients with BPDCN.
• To determine response rates and duration of response in untreated and relapsed BPDCN patients.
• To assess tagraxofusp's potential as a treatment for this rare cancer.

Main Methods:

• An open-label, multicohort study involving 47 patients with BPDCN.
• Patients received intravenous tagraxofusp (7 μg or 12 μg/kg) on days 1-5 of a 21-day cycle.
• Treatment continued until disease progression or unacceptable toxicity.

Main Results:

• In previously untreated patients receiving 12 μg/kg, 72% achieved the primary outcome (complete response/clinical complete response) with a 90% overall response rate.
• Survival rates at 18 and 24 months were 59% and 52%, respectively, in this group.
• Previously treated patients showed a 67% response rate and 8.5 months median overall survival.

Conclusions:

• Tagraxofusp induced clinical responses in adult patients with untreated or relapsed BPDCN.
• Common adverse events included elevated liver enzymes and thrombocytopenia.
• Serious adverse events like capillary leak syndrome occurred, necessitating careful monitoring.